Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

125.60 

0.50 0.4%

as of Feb 18 '19

52 Week Range:

107.50 155.95


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Ipsen S.A. operates as a pharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in oncology, endocrinology, neurology, gastroenterology, cognitive disorders, and rheumatology areas. Its products include Somatuline, which is an injectable treatment for acromegaly and neuroendocrine tumors; Cabometyx, a tablet formulation of cabozantinib for renal cell carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, and female sterility; and Dysport for motor disorders and muscular spasticity. The company also provides NutropinAq, a liquid formulation, for treating growth failure in children due to growth hormone deficiency in adults; and Increlex used for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta, a formulation for use in the treatment of chronic and acute diarrhea; Forlax, an osmotic laxative indicated for the symptomatic treatment of constipation in adults and children; Fortrans for the treatment of intestinal cleaning; Eziclen, an osmotic laxative indicated for the cleaning of bowel; Etiasa for the treatment of inflammatory bowel diseases; and Tanaka for mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for the treatment of gout; Prontalgine, an analgesic for the treatment of moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. Ipsen S.A. has a strategic agreement with Arix Bioscience plc to develop and commercialize various therapies. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Equity (BVPS) 10.31
11.68
12.97
12.74
11.11
11.31
11.94
13.78
15.23
16.93
20.16
growth rate 13.3% 11.0% -1.8% -12.8% 1.8% 5.6% 15.4% 10.5% 11.2% 19.1%
Earnings BIT 180.48
167.31
125.40
41.37
120.26
226.20
249.50
313.60
348.20
400.40
556.30
growth rate -7.3% -25.1% -67.0% 190.7% 88.1% 10.3% 25.7% 11.0% 15.0% 38.9%
Avg.PE 16.00
20.96
20.20
10,000.00
19.92
20.20
24.34
28.47
32.38
37.76
26.73
growth rate 31.0% -3.6% 49,405.0% -99.8% 1.4% 20.5% 17.0% 13.7% 16.6% -29.2%
ROA 10.17
9.95
5.85
0.03
-1.85
9.76
9.36
10.40
10.36
9.91
12.08
growth rate -2.2% -41.2% -99.5% -100.0% 100.0% -4.1% 11.1% -0.4% -4.3% 21.9%
ROE 17.66
16.93
9.25
0.04
-3.04
16.09
15.07
16.60
17.50
18.88
23.14
growth rate -4.1% -45.4% -99.6% -100.0% 100.0% -6.3% 10.2% 5.4% 7.9% 22.6%
ROIC 14.26
15.54
9.03
0.15
-2.71
16.26
15.25
16.61
14.40
15.75
22.86
growth rate 9.0% -41.9% -98.3% -100.0% 100.0% -6.2% 8.9% -13.3% 9.4% 45.1%
Cur. Ratio 2.18
2.11
1.92
1.71
1.39
1.60
1.64
1.75
1.87
1.08
1.23
growth rate -3.2% -9.0% -10.9% -18.7% 15.1% 2.5% 6.7% 6.9% -42.3% 13.9%
Quick Ratio 1.46
1.44
1.26
1.09
0.85
1.00
1.05
1.18
1.42
0.74
0.85
growth rate -1.4% -12.5% -13.5% -22.0% 17.7% 5.0% 12.4% 20.3% -47.9% 14.9%
Leverage 1.81
1.60
1.56
1.61
1.69
1.61
1.61
1.59
1.78
2.01
1.83
growth rate -11.6% -2.5% 3.2% 5.0% -4.7% 0.0% -1.2% 12.0% 12.9% -9.0%
Balance Sheet Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Acct.Receivable 217.85
223.11
326.00
349.00
342.00
319.40
348.10
447.20
472.70
546.70
510.70
growth rate 2.4% 46.1% 7.1% -2.0% -6.6% 9.0% 28.5% 5.7% 15.7% -6.6%
Acct.Payable 141.00
150.00
160.00
154.80
179.80
195.10
241.50
319.10
379.80
growth rate 6.4% 6.7% -3.3% 16.2% 8.5% 23.8% 32.1% 19.0%
Cur.Assets 688.63
652.36
640.00
633.00
606.00
601.80
671.60
809.80
1,050.40
1,016.40
1,185.60
growth rate -5.3% -1.9% -1.1% -4.3% -0.7% 11.6% 20.6% 29.7% -3.2% 16.7%
Total Assets 1,564.40
1,576.90
1,678.00
1,633.00
1,562.00
1,565.30
1,713.30
1,938.00
2,423.50
3,072.00
3,377.40
growth rate 0.8% 6.4% -2.7% -4.4% 0.2% 9.5% 13.1% 25.1% 26.8% 9.9%
Cash 239.60
218.60
178.00
145.00
114.00
131.00
186.30
226.10
425.50
228.00
344.50
growth rate -8.8% -18.6% -18.5% -21.4% 14.9% 42.2% 21.4% 88.2% -46.4% 51.1%
Inventory 115.78
102.97
112.00
118.00
128.00
121.50
105.50
107.40
113.30
167.40
198.50
growth rate -11.1% 8.8% 5.4% 8.5% -5.1% -13.2% 1.8% 5.5% 47.8% 18.6%
Cur.Liabilities 316.05
308.01
333.00
370.00
437.00
376.20
410.20
461.50
561.30
941.80
959.20
growth rate -2.5% 8.1% 11.1% 18.1% -13.9% 9.0% 12.5% 21.6% 67.8% 1.9%
Liabilities 677.80
594.20
599.00
618.00
657.00
591.60
645.40
712.40
1,061.30
1,536.10
1,534.00
growth rate -12.3% 0.8% 3.2% 6.3% -10.0% 9.1% 10.4% 49.0% 44.7% -0.1%
LT Debt 148.90
12.20
15.00
17.00
16.00
12.30
12.10
20.60
314.80
400.30
386.00
growth rate -91.8% 23.0% 13.3% -5.9% -23.1% -1.6% 70.3% 1,428.2% 27.2% -3.6%
Equity 886.60
984.30
1,079.20
1,015.40
904.50
971.50
1,065.20
1,222.50
1,358.90
1,525.40
1,841.10
growth rate 11.0% 9.6% -5.9% -10.9% 7.4% 9.6% 14.8% 11.2% 12.3% 20.7%
Common Shares 84.00
84.00
85.00
83.00
83.00
83.00
82.00
83.00
83.00
83.00
83.00
growth rate 0.0% 1.2% -2.4% 0.0% 0.0% -1.2% 1.2% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Capital Expenditures 61.40
40.30
54.00
44.00
49.00
42.00
45.50
49.80
81.10
84.50
107.40
growth rate -34.4% 34.0% -18.5% 11.4% -14.3% 8.3% 9.5% 62.9% 4.2% 27.1%
Cash Dividends 55.00
58.00
62.30
66.50
66.50
66.60
65.50
70.00
70.00
70.20
83.00
growth rate 5.5% 7.4% 6.7% 0.0% 0.2% -1.7% 6.9% 0.0% 0.3% 18.2%
Cash From OA 203.70
257.60
252.00
175.00
144.00
188.10
245.80
223.60
317.80
422.90
570.90
growth rate 26.5% -2.2% -30.6% -17.7% 30.6% 30.7% -9.0% 42.1% 33.1% 35.0%
FCF per Share 1.29
2.28
1.98
1.31
0.74
0.88
1.38
1.77
0.43
0.63
3.37
growth rate 76.7% -13.2% -33.8% -43.5% 18.9% 56.8% 28.3% -75.7% 46.5% 434.9%
Sale Purchase of Stock 0.80
3.10
5.40
12.70
6.90
growth rate 287.5% 74.2% 135.2% -45.7%
FCF 108.00
193.00
167.00
73.00
61.00
126.00
161.00
148.00
-55.00
182.00
283.00
growth rate 78.7% -13.5% -56.3% -16.4% 106.6% 27.8% -8.1% -100.0% 100.0% 55.5%
Income Statement Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18
Sales 1,038.10
1,112.40
1,170.00
1,210.00
1,277.00
1,281.80
1,332.40
1,520.20
1,671.10
2,011.80
2,348.40
growth rate 7.2% 5.2% 3.4% 5.5% 0.4% 4.0% 14.1% 9.9% 20.4% 16.7%
Op.Income 179.18
172.47
96.00
74.00
97.00
226.20
249.50
313.60
348.20
400.40
556.30
growth rate -3.7% -44.3% -22.9% 31.1% 133.2% 10.3% 25.7% 11.0% 15.0% 38.9%
IBT 190.90
167.30
125.40
71.90
122.60
201.50
208.30
240.10
299.90
372.00
495.20
growth rate -12.4% -25.0% -42.7% 70.5% 64.4% 3.4% 15.3% 24.9% 24.0% 33.1%
Net Income 147.10
157.20
96.00
74.00
97.00
152.50
153.50
189.90
225.90
272.30
389.50
growth rate 6.9% -38.9% -22.9% 31.1% 57.2% 0.7% 23.7% 19.0% 20.5% 43.0%
EPS 1.74
1.86
1.13
0.01
-0.34
1.83
1.87
2.30
2.73
3.28
4.68
growth rate 6.9% -39.3% -99.1% -100.0% 100.0% 2.2% 23.0% 18.7% 20.2% 42.7%
Gross Profit 818.00
874.60
931.00
961.00
1,023.00
976.50
1,022.40
1,183.40
1,320.00
1,626.20
1,894.20
growth rate 6.9% 6.5% 3.2% 6.5% -4.6% 4.7% 15.8% 11.5% 23.2% 16.5%
R&D 195.80
186.90
192.60
231.30
265.80
302.10
growth rate -4.6% 3.1% 20.1% 14.9% 13.7%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 108.05
142.80
142.80
135.35
135.35
growth rate 32.2% 0.0% -5.2% 0.0%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 546.70
497.90
497.90
510.70
510.70
growth rate -8.9% 0.0% 2.6% 0.0%
Acct.Payable 319.10
325.20
325.20
379.80
379.80
growth rate 1.9% 0.0% 16.8% 0.0%
Cur.Assets 1,016.40
1,180.20
1,180.20
1,185.60
1,185.60
growth rate 16.1% 0.0% 0.5% 0.0%
Total Assets 3,072.00
3,295.50
3,295.50
3,377.40
3,377.40
growth rate 7.3% 0.0% 2.5% 0.0%
Cash 228.00
359.30
359.30
344.50
344.50
growth rate 57.6% 0.0% -4.1% 0.0%
Inventory 167.40
188.30
188.30
198.50
198.50
growth rate 12.5% 0.0% 5.4% 0.0%
Cur.Liabilities 941.80
1,054.40
1,054.40
959.20
959.20
growth rate 12.0% 0.0% -9.0% 0.0%
Liabilities 1,536.10
1,627.70
1,627.70
1,534.00
1,534.00
growth rate 6.0% 0.0% -5.8% 0.0%
LT Debt 400.30
380.90
380.90
386.00
386.00
growth rate -4.9% 0.0% 1.3% 0.0%
Equity 1,525.40
1,665.30
1,665.30
1,841.10
1,841.10
growth rate 9.2% 0.0% 10.6% 0.0%
Common Shares 83.70
83.80
83.80
83.80
83.80
growth rate 0.1% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures 28.35
17.60
17.60
36.10
36.10
growth rate -37.9% 0.0% 105.1% 0.0%
Cash Dividends 41.50
41.50
41.50
growth rate 0.0% 0.0%
Cash From OA 146.65
104.50
104.50
180.95
180.95
growth rate -28.7% 0.0% 73.2% 0.0%
Sale Purchase of Stock 1.70
2.20
2.20
growth rate 29.4% 0.0%
FCF 118.30
86.90
86.90
144.85
144.85
growth rate -26.5% 0.0% 66.7% 0.0%
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 521.05
562.55
562.55
611.65
611.65
growth rate 8.0% 0.0% 8.7% 0.0%
Op.Income 108.05
142.80
142.80
135.35
135.35
growth rate 32.2% 0.0% -5.2% 0.0%
IBT 103.15
128.50
128.50
119.10
119.10
growth rate 24.6% 0.0% -7.3% 0.0%
Net Income 73.20
98.75
98.75
96.00
96.00
growth rate 34.9% 0.0% -2.8% 0.0%
EPS
growth rate
Gross Profit 423.35
454.35
454.35
492.75
492.75
growth rate 7.3% 0.0% 8.5% 0.0%
R&D 75.40
70.80
70.80
80.25
80.25
growth rate -6.1% 0.0% 13.4% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (90.86)

YOY Growth Grade:

C (51.82)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 26.73 26.84 17.77
EPS / Growth 22.1% 4.68 23.1%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 12.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 12.3% 19.2% 19.2%
Future PE 17.77 27.61 27.61
Future EPS 14.96 27.03 27.03
Value Price
MOS %
65.69
-47.7%
184.52
46.9%
184.52
46.9%
MOS Price 32.85 92.26 92.26
IRT 11.80 9.51 9.51

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.